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Abstract
Background: Cross national drug utilization studies can provide information about different
influences on physician prescribing. This is important for medicines with issues around safety and
quality of use, like non selective non-steroidal anti-inflammatory drugs (ns-NSAIDs) and cyclo-
oxygenase-2 (COX-2) inhibitors. To enable comparison of prescription medicine use across
different jurisdictions with a range of population sizes, data first need to be compared within
Australia to understand whether use in a smaller sub-population may be considered as
representative of the total use within Australia. The aim of this study was to compare the utilization
of non selective NSAID, COX-2 inhibitors and paracetamol between Queensland and Australia.
Method: Dispensing data were obtained for concession beneficiaries for Australia for ns-NSAIDs,
COX-2 inhibitors and paracetamol subsidized by the PBS over the period 1997–2003. The same
data were purchased for Queensland. Data were converted to Defined Daily Dose (DDD)/1000
beneficiaries/day (World Health Organization anatomical therapeutic chemical classification, 2005).
Results: Total NSAID and paracetamol consumption were similar in Australia and Queensland.
Ns-NSAID use decreased sharply with the introduction of COX-2 inhibitors (from approximately
80 to 40 DDD/1000 beneficiaries/day). Paracetamol was constant (approximately 45 DDD/1000
beneficiaries/day). COX-2 inhibitors consumption was initially higher in Queensland than in the
whole of Australia.
Conclusion: Despite initial divergence in celecoxib use between Queensland and Australia, the
use of ns-NSAIDs, COX-2 inhibitors and paracetamol overall, in concession beneficiaries, was
comparable in Australia and Queensland.
Background
International comparisons of drug use provide bench-
marking data and represent a valuable strategy to achieve
a better understanding of use of medicines. Cross national
drug utilization studies can provide information on differ-
ences in the effect of access to drug programs, the effect of
formulary policies and the influences on physician pre-
scribing (education interventions, industry and marketing
efforts) to explain some of the prescribing variations.
Exploration of the similarities and differences in use is a
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helpful strategy for planning and improving practices in
drug approval, regulation, financing, reimbursement, pre-
scribing and use by patients. In the European Union for
example, Eurodurg http://www.eurodurg.com, was cre-
ated to promote the drug utilization research across
Europe. In Australia the National Prescribing Service
(NPS) has used various techniques to improve drug pre-
scribing and use by patients, including academic detail-
ing, audit and feedback and social marketing. However,
little research has been done comparing Australian drug
use with that of other countries. According to the World
Health Organization (WHO) "the Australian health system
is world-class in both its effectiveness and efficiency: Australia
consistently ranks in the best performing group of countries for
healthy life expectancy and health expenditure per person.'
(World Health Organization 2003). Hence, exploring
similarities and differences with the Australian drug utili-
zation patterns may be a valuable opportunity for other
countries for planning and developing new ideas for phar-
maceutical policy or for education. Reciprocally, the Aus-
tralian healthcare scheme may further benefit from
international comparison study outcomes.
Queensland, one state in Australia, has been shown in a
previous study on antilipemic drugs to be suitable for
international comparison purposes (to Nova Scotia, one
province in Canada) for that group of medicines [1].
Queensland was shown to have a population of similar
gender and age distribution, and similar health risk factor
exposures, to Nova Scotia. Comparing drug use in
Queensland and Nova Scotia has produced very interest-
ing comparisons and contrasts for the statin drugs [1].
These data have provided some useful ideas for changes to
influence potentially inappropriate use of those medi-
cines, and also demonstrated that such comparisons can
be done between Nova Scotia and Queensland. However,
there are advantages in being able to compare to Australia-
wide prescription drug use, rather than use in individual
states. Accessing data from the individual states in Aus-
tralia is expensive and data are purchased often with long
time delay. On the other hand, accessing Australian data
(for the whole country) is rapid and inexpensive. Austral-
ian data are freely available on the Medicare Australia
website http://www.medicareaustralia.gov.au/statistics/
dyn_pbs/forms/pbs_tab1.shtml and the database is
updated each month.
The non-selective non-steroidal anti-inflammatory drugs
(ns-NSAIDs) are a class of drug used widely [2]. NSAIDs
are one of the classes of drugs most prescribed worldwide
[2]. However, concern over the overall NSAID consump-
tion has arisen due to issues around their toxicity [2] and
also because of their high patterns of utilisation, often in
inappropriate population groups [3].
NSAIDs have been used to decrease pain and inflamma-
tion for major and minor musculoskeletal disorders for
years [4-6]. The most common adverse effect associated
with ns-NSAIDs depends on the regulation of the protec-
tive mechanisms involving the GI mucosa. GI adverse
effects to Ns-NSAIDs were originally proposed to be
related to inhibition of one type of enzyme, cyclo-oxyge-
nase-1 (COX-1), and specific drugs (COX-2 inhibitors)
were developed to inhibit mainly the 'inducible' cyclo-
oxygenase associated with inflammation, cyclo-oxygen-
ase-2 (COX-2) [7]. In 2000, 2001, and 2002 celecoxib,
rofecoxib and meloxicam, respectively, three COX-2
inhibitors, were made available in Australia. COX-2
inhibitors were introduced with the recommendation to
limit their use to those patients at high risk of GI compli-
cations, to those not responding to traditional ns-NSAID
therapy or with concomitant use of corticosteroids, anti-
coagulants and advanced age [8]. However, immediately
after their launch on the market a very rapid uptake of use
was observed in different countries suggesting that pre-
scribing of those medicines has been excessive [9-16].
The need to improve the safe, appropriate cost effective
prescribing of NSAIDs has been recognized in different
countries [17,18]. As a consequence, a number of strate-
gies have been planned and implemented to improve and
optimize NSAID utilization [17,18]. In 2002, the Austral-
ian Government designated arthritis and musculoskeletal
conditions as a National Health Priority Area with the aim
of improving quality of life for people with those diseases
[17]. In 2003, the NPS started an educational program
known as "Optimizing safe and effective use of analgesics in
musculoskeletal pain" and in August 2006, an academic
detailing program on the same topic was repeated ("Anal-
gesic choices in persistent pain, focusing on best practice anal-
gesic treatment in persistent, non-cancer pain").
The aim of this study was to compare the utilization of ns-
NSAIDs, COX-2 inhibitors and paracetamol, in seniors
and welfare recipients, between Queensland and Australia
in order to determine whether the sub-group, Queens-
land, was representative of total Australian NSAID utiliza-
tion over the period when COX-2 inhibitors were
introduced into Australia. For future planned interna-
tional studies of NSAID utilization patterns comparison
to the whole of Australia data would be quicker (internet
access), cheaper (no cost for Australia collated data) and
easier than having to purchase and wait for individual
State data.
Method
Medicare Australia is the agency responsible for payment
to community pharmacists for prescription medicines
reimbursed by the Pharmaceutical Benefit Scheme (PBS).
The PBS subsidizes specific prescription medicines for allBMC Health Services Research 2008, 8:196 http://www.biomedcentral.com/1472-6963/8/196
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Australian residents (national, universal scheme). All the
reimbursable prescribed drugs dispensed are recorded in a
database, with aggregated, de-identified data publicly
accessible through a website [19]. The data are presented
aggregated by item number (a code given to each formu-
lation of each compound for medicines subsidized by the
PBS). There are two classes of PBS beneficiaries, general
and concession. Concession beneficiaries consist of those
Australian residents eligible for the Commonwealth Sen-
iors Health Card, Health Care Card and Pensioner Con-
cession Card. These are people receiving old age or
disability pensions, single parents, low income families
and other patients eligible for a social security benefit.
They contribute a low co-payment (currently AUD$4.90),
general beneficiaries contribute with higher co-payments
(currently AUD$30.70).
The numbers of prescriptions dispensed during the period
January 1997 and December 2003, for the whole Aus-
tralia, for concession beneficiaries for non-selective non-
steroidal anti-inflammatory drugs (ns-NSAIDs), COX-2
inhibitors (celecoxib, rofecoxib and meloxicam) and
paracetamol were downloaded from the Medicare Aus-
tralia website http://www.medicareaustralia.gov.au/statis
tics/dyn_pbs/forms/pbs_tab1.shtml. The same data for
Queensland were purchased by request from Medicare
Australia.
The numbers of eligible concession beneficiaries for each
month between January 1997 and December 2003 were
obtained by request from Centrelink (the government
agency responsible for social services for the Australian
community). Australian over 65 years of age are the main
beneficiaries of the PBS, responsible for the highest drug
consumption [20]. It has been estimated that concession
beneficiaries receive approximately 80% of all the PBS
subsidized medications. [20]. Moreover, they are the
group with highest prevalence of musculoskeletal disor-
ders and most likely to be prescribed the drugs of interest
[21]. Conditions approved in Australia for reimburse-
ment of NSAIDs and paracetamol are chronic arthropa-
thies, persistent pain associated with osteoarthritis,
symptomatic treatment of osteoarthritis, and sympto-
matic treatment of rheumatoid arthritis [22].
The generic compounds were classified according to the
World Health Organization (WHO) Anatomical Thera-
peutic Chemical (ATC) classification system 2005 [23].
The ATC M01A, N02BA01 (aspirin), N02BA11 (diflu-
nisal) and N02BE01 (paracetamol) included all the drugs
for this study. The number of defined daily dose (DDD)
per 1000 concession beneficiaries per day were calculated
(for each year) as follows:
1. Total annual consumption of the drug in grams was
first calculated and then converted into total DDDs using
the following equation:
• Total grams = (N * M * Q)
Where N is the number of PBS services for that item reim-
bursed; M is the strength of each unit (eg. tablet, capsule
etc) and Q is the quantity of units in each service (package
size).
￿ Total DDDs = Total grams/DDDWHO
Where DDDWHO is the DDD as designated by the WHO
(2005).
2. The number of DDDs was then divided by the conces-
sion card holder population numbers and the number of
days. Hence, drug utilization was expressed as DDD/1000
concession beneficiaries/day and calculated as follows:
DDD/1000 concession beneficiaries/day = total DDDs/
(no. of concession beneficiaries/1000 × 365).
The mean DDD/1000 beneficiaries/day for all NSAIDs
and paracetamol was compared between Queensland and
in the whole of Australia.
DDDs calculations were completed using Microsoft Office
Excel 2003 (Microsoft Corporation, Redmond, Washing-
ton) and statistical analysis was performed with Origin
6.0 (OriginLab Corporation, Northampton, MA USA).
Differences were considered statistically significant if P <
0.05.
Drug Utilization 90% (DU90%) for all NSAIDs was also
calculated [24]. DU90% includes those drugs accounting
for 90% of prescriptions within the group of medicines
being studied. Data were first expressed as DDD/1000
beneficiaries/day, then percentage of utilization of the
total NSAIDs was calculated for each drug. The DU90%
comprises those most used, those which summed to 90%
of the total consumption [24].
Low-, moderate-, and high-risk of gastrointestinal side
effect groups were identified for the ns-NSAIDs as defined
by the Gastroenterological Society of Australia [25]. This
classification was in agreement with other sources in the
literature [26-28]. Ibuprofen and diclofenac were classi-
fied as low risk; aspirin, sulindac, naproxen and
indomethacin as moderate risk; and ketoprofen and
piroxicam as high risk for GI side effects.BMC Health Services Research 2008, 8:196 http://www.biomedcentral.com/1472-6963/8/196
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Results
General demographic data, health status data, utilization
of health care services and risk factors were similar when
comparing Queensland (subset of national population)
to the whole of Australia (Table 1). The population in
Australia and Queensland were respectively 20,091,500
and 3,888,077 at June 2004 [29]. In both geographical
areas concession beneficiaries cards holder accounted for
24.7% of the population (4,963,281 in Australia and
958,405 in Queensland).
In Figure 1, ns-NSAIDs and overall NSAIDs dispensing
data for concession beneficiaries, over the period 1997–
2003, in Australia and Queensland are shown. Ns-NSAID
consumption in concession beneficiaries was similar in
Australia and in Queensland. Ns-NSAID use decreased
sharply with the introduction of COX-2 inhibitors (from
approximately 80 to 40 DDD/1000 concession beneficiar-
ies/day) (Figure 1). COX-2 inhibitors uptake was high in
the period 2000–2003. The overall use of COX-2 inhibi-
tors started at about 60 and 40 DDD/1000 concession
beneficiaries/day, respectively in Queensland and Aus-
tralia, when celecoxib was introduced into Australia
(2000). There was initial different use of COX-2 inhibi-
tors: 55 DDD/1000 concession beneficiaries in Queens-
land vs 36 DDD/1000 concession beneficiaries in
Australia (P = 0.46) (Figure 2). However, as the other
COX-2 inhibitors (rofecoxib and meloxicam) came on to
the market (2002), use rapidly became similar in Australia
and in Queensland (approximately 45 DDD/1000 con-
cession beneficiaries/day) (Figure 2).
Paracetamol consumption was similar in Australia and
Queensland and it was constant over the time.
DU90% patterns were similar in Australia and Queens-
land (Table 2). Major changes were seen in both jurisdic-
tions after the introduction of COX-2 inhibitors. DU90%
Table 1: Demographics and relevant health status: Comparison between Queensland and Australia.
Demographics and relevant health status: comparison between Queensland and Australia
QLD AUS
Demographics and health status
Demographics
• Total adults aged 65 and over 12% 13%
• Males aged 65 and over 46% 45%
• Females aged 65 and over 54% 55%
Health Status – Prevalence of musculoskeletal disease as a long term condition
• Total Musculoskeletal disease 34% 32%
 Arthritis 14% 14%
 Rheumatism 1% 1%
 Back pain/problems neck/disc disorders 23% 21%
 Osteoporosis 2% 2%
 Other 5% 5%
Utilisation of health care services
• Average Medicare services processed per person 11 11
• Average Medicare services processed per person aged ≥ 65 22 23
• Pension Card and Commonwealth Seniors health cards as a proportion of all concessions 60% 64%
Pharmaceutical Benefit Scheme (services related to the musculoskeletal system)
• Average number of services per person 88
Pharmaceutical Benefit Scheme (overall)
• Average number of services per person 11
Risk factors
• Overweight/obese adults (males aged 18 and over) 56% 54%
• Overweight/obese adults (females aged 18 and over) 41% 38%
• Adults who are physically inactive males aged 18 and over 40% 42%
• Adults who are physically inactive females aged 18 and over 31% 31%
Data extracted from the 2001 Australian Census and Medicare Australia annual report 2000–2001 and 2002–2003 [45]BMC Health Services Research 2008, 8:196 http://www.biomedcentral.com/1472-6963/8/196
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showed that before the COX-2 inhibitors introduction,
naproxen and diclofenac were the most used ns-NSAIDs
(1997–1999). When COX-2 inhibitors took over, these
ns-NSAIDs were progressively replaced and celecoxib and
rofecoxib became the most used anti-inflammatory drugs
(2000–2003) (Table 2).
Discussion
The data collected in this study indicate that Australian
data as a whole, for concession beneficiaries, were compa-
rable to data from Queensland, in terms of ns-NSAIDs,
COX-2 inhibitors and paracetamol. Queensland had only
about 19% of the population of Australia, so it was not
the major 'driver' of use, indicating that this finding was
not simply due to measuring drug use in a majority group
which subsequently determined overall use in the whole
population.
Celecoxib use in Australia and Queensland was initially
different when the drug was first listed on the PBS (2000)
(Figure 2). However, the difference observed was not sta-
tistically significant (P ≥ 0.05). The overall COX-2 inhibi-
tors, and consequently the total NSAID use became
essentially the same in Australia and Queensland by 2002
(Figure 1 and 2). Reasons for this initial difference were
explored. Evidence was lacking about any specific initia-
tives which may have made Queensland prescribing of
celecoxib any different to that of the rest of Australia, how-
ever, possible reasons are interesting to speculate about.
Celecoxib was the first COX-2 inhibitor marketed in Aus-
tralia and approved for listing on the national formulary
of reimbursable medications (PBS). Celecoxib was listed
as a restricted benefit for symptomatic treatment of oste-
oarthritis (OA) and rheumatoid arthritis (RA). OA is the
most common musculoskeletal condition, affecting more
than 1.6 million Australian while RA affects a much
smaller group[21]. OA incidence rises with age affecting
mainly people over 65 years of age[21]. However, preva-
lence of disease was similar in Queensland and in the
whole Australian population, so this cannot account for
any initial differences in COX-2 uptake (Table 1). Also,
the older population (over 65 years of age) has been cal-
The ns-NSAID and COX-2 inhibitor prescription pattern in concession beneficiaries in Australia and in Queensland between  1997 and 2003 Figure 1
The ns-NSAID and COX-2 inhibitor prescription pattern in concession beneficiaries in Australia and in 
Queensland between 1997 and 2003.BMC Health Services Research 2008, 8:196 http://www.biomedcentral.com/1472-6963/8/196
Page 6 of 9
(page number not for citation purposes)
culated to be very similar in Queensland and in the whole
of Australia (13% of the whole Australian population and
12% in Queensland) so this also cannot account for the
initial differences seen in celecoxib use [29].
A possible explanation of the differences observed in the
celecoxib prescribing initially, could have been attributed
to a higher older population in Queensland, compared to
the rest of Australia, and consequently, to higher disease
prevalence (OA). However, in our study, comparison of
selected indicators such as of demographic data, health
status data, utilization of health care services and risk fac-
tors between Queensland and Australia did not sustain
this as an explanation (Table 1). There is the common per-
ception that the older population might be increasing in
Queensland because the trend for retirement is to move to
coastal areas in Queensland[21,30]. However, socio-eco-
nomic and demographic data do not support this percep-
tion [29]. The number and distribution of retirement
homes in Australia also shows no disproportionate distri-
bution http://www.retirementlivingonline.com.au[29].
Another explanation investigated was the possibility of
heavier marketing activity or more press releases in
Queensland. However, despite the fact that some infor-
mation can be sourced in the literature about celecoxib
marketing activity in Australia and this potential influence
on prescribing behaviour [10,31], no evidence was found
to differentiate marketing strategies used in the different
States within Australia. There were also no obvious differ-
ences in opinion leaders' influence in the different States,
although this can not be discounted as this is not quanti-
fied in anyway.
Associations between prescribing behaviour and physi-
cian characteristics (age, gender and years from gradua-
tion for example) have been described [32,33]. Volume of
prescription has been reported to be related to updated
knowledge about the relative risks and benefits of drugs
with similar indications (ns-NSAIDs versus COX-2 inhib-
itors or paracetamol in this case) [33]. Younger physician,
who have been trained more recently, seemed to have
higher familiarity with the benefits emerging from new
therapies whereas more experienced prescribers might be
more critical about the possible risks [33]. However, in
Australia it is not possible to identify the prescriber, and
the lack of linked information to the prescribing data did
COX-2 inhibitor prescription pattern in concession beneficiaries in Australia and in Queensland between 2000 and 2003 Figure 2
COX-2 inhibitor prescription pattern in concession beneficiaries in Australia and in Queensland between 2000 
and 2003.BMC Health Services Research 2008, 8:196 http://www.biomedcentral.com/1472-6963/8/196
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not allow a deeper analysis to determine any association
with prescriber characteristics or whether different geo-
graphical areas differed in respect to physician characteris-
tics. The lack of linked information was one of the main
limitations of the study.
In Australia prescription data are also not linked to other
data sources (e.g. medical services or hospitalizations).
Consequently, it was not possible to establish from our
data if the prescription of any of the drugs was appropri-
ate, if those drugs were prescribed for the correct indica-
tions (e.g. correct dosage and/or duration), or if
prescriptions came from general practitioners or special-
ists; neither was it possible to complete any analysis of co-
morbidity or co-prescription.
Despite the initial difference in celecoxib use, the intro-
duction of the COX-2 inhibitors led to a progressive
increase in total NSAID use whereas paracetamol use
remained steady both in Queensland and Australia. It is
possible that an increase in patients (concession benefici-
aries) treated may have raised the number of NSAID pre-
scriptions. However, prevalence of disease does not
appear to have changed over this relatively short time
period.
Patterns in drug use can vary from region to region for rea-
sons such as differences in the local guidelines, general
cultural background, personal history of health practi-
tioners' (e.g. education received and country of origin),
patients' characteristics, and healthcare systems (e.g. reim-
bursement plans, health policies) [32]. In Australia, phar-
maceutical reimbursement plans and health policies are
organized at a national level, this means that the same
rules for coverage and reimbursement apply to the
Queensland and to the overall Australian concession ben-
eficiaries. Moreover, no differences in patients' character-
istics (e.g. age and gender, risk factors, general, prevalence
of musculoskeletal disease, and utilization of healthcare
services) were observed between Queensland and Aus-
tralia (Table 1).
The first-line therapy recommended for people with
chronic pain such as OA is generally paracetamol [31,34-
36]. At therapeutic doses, paracetamol is considered safer
than other anti-inflammatory drugs and it is much
cheaper than ns-NSAIDs and COX-2 inhibitors [37].
However, paracetamol prescribing has been very steady all
over the period (1997–2003), both in Queensland and in
Australia as a whole, which is a little disappointing con-
sidering the potential benefits. Paracetamol is a much
safer option for elderly suffering from musculoskeletal
conditions. It is possible that concession beneficiaries
may have received paracetamol as an adjuvant during
NSAID therapy. However, in Australia it is not possible to
identify co-prescriptions.
The overall change in drug use can be identified in the
DU90% profiles (Table 2). DU90% was introduced by Berg-
man et al. as a source for more specific analysis of quality
in prescribing [24]. DU90% can be used in a number of
ways, for example, to look at trends or changes in drug
Table 2: DU90% in Queensland and in Australia for the overall NSAID utilization in Concession beneficiaries between 1997 and 2003
Australia DU90%
1997–1999% 2000% 2001% 2002% 2003%
Naproxen* 28 Celecoxib+ 35 Celecoxib+ 40 Celecoxib+ 39 Celecoxib+ 35
Diclofenac** 21 Naproxen* 20 Rofecoxib+ 16 Rofecoxib+ 22 Rofecoxib+ 25
Ketoprofen# 16 Diclofenac** 15 Naproxen* 16 Naproxen* 12 Diclofenac** 12
Piroxicam# 10 Ketoprofen# 9 Diclofenac** 14 Diclofenac** 12 Naproxen* 11
Indomethacin* 7 Piroxicam# 7 Ketoprofen# 7 Ketoprofen# 5 Meloxicam+ 9
Ibuprofen** 6 Ibuprofen** 5
Queensland DU90%
1997–1999% 2000% 2001% 2002% 2003%
Naproxen* 27 Celecoxib+ 45 Celecoxib+ 43 Celecoxib+ 40 Celecoxib+ 35
Diclofenac** 20 Naproxen* 14 Rofecoxib+ 16 Rofecoxib+ 22 Rofecoxib+ 26
Ketoprofen# 17 Diclofenac** 13 Naproxen* 10 Diclofenac** 9 Diclofenac** 9
Piroxicam# 12 Ketoprofen# 8 Diclofenac** 10 Naproxen* 9 Meloxicam+ 8
Ibuprofen** 9 Ketoprofen# 5 Ibuprofen** 5 Naproxen* 8
Indomethacin* 5 Ibuprofen** 5 Ketoprofen# 4I b u p r o f e n * *  5
+ Cox-2 inhibitors ** ns-NSAIDs low risk # ns-NSAIDs high risk * ns-NSAIDs moderate riskBMC Health Services Research 2008, 8:196 http://www.biomedcentral.com/1472-6963/8/196
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use, as is done here, or on an individual basis to encour-
age health practitioners to evaluate their prescribing
behavior, compared to others, to enable them to review
the drugs included in their personal formulary [38]. The
DU90% for Australia and Queensland were very similar all
over the period, showing the marked change from ns-
NSAIDs to the predominant use of COX-2 inhibitors.
The prescription patterns in this study agreed with data
from other studies. Mamdani et al. showed that in their
population cohort (also elderly aged 66 and over) NSAID
use had increased by 41% and the rise was entirely due to
the uptake of COX 2 inhibitors [39]. Similarly, before
rofecoxib withdrawal, COX-2 inhibitor prescribing
increased the overall use of the NSAID class in Scotland,
Germany, Norway, Ireland and Portugal [40-44].
The ATC/DDD index chosen for consistent use for this
study was the 2005 version. The WHO recommends use
of a consistent dated version, rather than changing the
DDD mid-way through a study time. However, in 2003
the assigned DDD for rofecoxib had changed from 12.5
mg to 25 mg. Clinical practice had changed during this
time, with the more common dosage increasing. There-
fore applying the later DDD (25 mg) to earlier than 2003
data could have led to an underestimate in the actual
number of DDD used. For the early years, therefore, use of
rofecoxib may have actually been higher than that
reported here, due to an artifact of the changing DDD and
changing clinical practice. However, for the purposes of
the present study this would not alter any conclusions,
nor any of the comparisons described here, as the same
artifact would be present for the Queensland state data as
for all the Australian data.
In conclusion, this study showed that despite the initial
divergences in celecoxib use between Queensland and
Australia, the use of ns-NSAIDs, COX-2 inhibitors and
paracetamol overall, in concession beneficiaries, was
comparable in Australia and Queensland. The differences
observed were only temporary, when this new class of
drugs was first introduced. Both jurisdictions demonstrate
an overall increase in NSAID use following the introduc-
tion of COX-2 inhibitors. Australian data may be a valid
alternative to Queensland data for future international
comparison studies on ns-NSAIDs and COX-2 inhibitors
utilization. By using Australian data time delays and costs
will decrease, facilitating the process of data collection.
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